PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 7267人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255121, encodeId=aaf3125512118, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=29, createdTime=2021-11-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255120, encodeId=8022125512015, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, objectType=article, longId=219447, objectId=234a21944e5a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234a21944e5a, replyNumber=0, likeNumber=0, createdTime=2021-10-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234a21944e5a, moduleTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234a21944e5a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255119, encodeId=f41d1255119cf, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制, objectType=article, longId=218860, objectId=c4e02188600e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e02188600e, replyNumber=0, likeNumber=95, createdTime=2021-10-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e02188600e, moduleTitle=Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4e02188600e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255118, encodeId=a571125511837, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, objectType=article, longId=217312, objectId=e46321e31264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46321e31264, replyNumber=0, likeNumber=105, createdTime=2021-09-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46321e31264, moduleTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46321e31264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255117, encodeId=e77e125511e04, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=34, createdTime=2021-09-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255116, encodeId=b05c1255116aa, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：α-PD-L1抗体±α-TIM-3抗体治疗MSI-H/dMMR肿瘤的活性和安全性, objectType=article, longId=216685, objectId=110121668513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=110121668513, replyNumber=0, likeNumber=145, createdTime=2021-09-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=110121668513, moduleTitle=Clin Cancer Res：α-PD-L1抗体±α-TIM-3抗体治疗MSI-H/dMMR肿瘤的活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=110121668513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255115, encodeId=2633125511531, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cell Metab：王红阳院士团队揭示NAD+代谢调节肿瘤免疫逃逸和增强PD-1/PD-L1治疗敏感性, objectType=article, longId=216078, objectId=9cf52160e830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cf52160e830, replyNumber=0, likeNumber=0, createdTime=2021-08-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cf52160e830, moduleTitle=Cell Metab：王红阳院士团队揭示NAD+代谢调节肿瘤免疫逃逸和增强PD-1/PD-L1治疗敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cf52160e830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255114, encodeId=58821255114dd, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=EBUS-TBNA样品中的PD-L1检测结果是否可以指导ICI治疗？, objectType=article, longId=216017, objectId=d6e421601e6c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6e421601e6c, replyNumber=0, likeNumber=119, createdTime=2021-08-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6e421601e6c, moduleTitle=EBUS-TBNA样品中的PD-L1检测结果是否可以指导ICI治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6e421601e6c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255113, encodeId=f3c512551133e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1测试在使用内核超声引导针吸入（EBUS-TBNA）中获得的大部分标本中是否可行？, objectType=article, longId=216013, objectId=df3021601387, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df3021601387, replyNumber=0, likeNumber=119, createdTime=2021-08-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df3021601387, moduleTitle=PD-L1测试在使用内核超声引导针吸入（EBUS-TBNA）中获得的大部分标本中是否可行？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3021601387)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255112, encodeId=18da12551129b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况, objectType=article, longId=215780, objectId=dc30215e8019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc30215e8019, replyNumber=0, likeNumber=66, createdTime=2021-08-17, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc30215e8019, moduleTitle=Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc30215e8019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255111, encodeId=3a7d125511178, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？, objectType=article, longId=215475, objectId=8fb22154e583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fb22154e583, replyNumber=0, likeNumber=89, createdTime=2021-08-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fb22154e583, moduleTitle=Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fb22154e583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255110, encodeId=336c1255110f9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Hematol Oncol ：我国不限瘤种PD-L1快要来了，晚期实体瘤患者精准治疗新选择！, objectType=article, longId=213845, objectId=5610213845c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5610213845c0, replyNumber=0, likeNumber=92, createdTime=2021-07-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5610213845c0, moduleTitle=J Hematol Oncol ：我国不限瘤种PD-L1快要来了，晚期实体瘤患者精准治疗新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5610213845c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255109, encodeId=1752125510938, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JNCI：三种PD-L1免疫组化分析方法对比及与三阴性乳腺癌患者治疗预后的相关性, objectType=article, longId=212568, objectId=05fd212568c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05fd212568c8, replyNumber=0, likeNumber=0, createdTime=2021-06-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05fd212568c8, moduleTitle=JNCI：三种PD-L1免疫组化分析方法对比及与三阴性乳腺癌患者治疗预后的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05fd212568c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255108, encodeId=bcd51255108d9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=陆舜教授：AI多组学深度学习预测肺癌免疫PD-1/PD-L1疗效, objectType=article, longId=207767, objectId=6a7120e767b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a7120e767b8, replyNumber=0, likeNumber=67, createdTime=2021-03-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a7120e767b8, moduleTitle=陆舜教授：AI多组学深度学习预测肺癌免疫PD-1/PD-L1疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a7120e767b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255107, encodeId=7300125510e98, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格, objectType=article, longId=207609, objectId=8af020e60938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8af020e60938, replyNumber=0, likeNumber=87, createdTime=2021-02-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8af020e60938, moduleTitle=是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8af020e60938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255106, encodeId=fbd7125510693, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：派姆单抗单药治疗PD-L1联合阳性评分≥10的胃/胃食管交界癌的疗效, objectType=article, longId=207294, objectId=4f3f20e2949c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f3f20e2949c, replyNumber=0, likeNumber=79, createdTime=2021-02-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f3f20e2949c, moduleTitle=Clin Cancer Res：派姆单抗单药治疗PD-L1联合阳性评分≥10的胃/胃食管交界癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f3f20e2949c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255105, encodeId=744e1255105ec, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：新型抗PD-L1抗体LY3300054治疗晚期实体瘤的疗效和安全性, objectType=article, longId=206739, objectId=b029206e3989, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b029206e3989, replyNumber=0, likeNumber=82, createdTime=2021-02-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b029206e3989, moduleTitle=Clin Cancer Res：新型抗PD-L1抗体LY3300054治疗晚期实体瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b029206e3989)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255104, encodeId=0ca11255104f0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）, objectType=article, longId=206606, objectId=61362066067d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61362066067d, replyNumber=0, likeNumber=81, createdTime=2021-02-03, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61362066067d, moduleTitle=J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61362066067d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255103, encodeId=f148125510332, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌, objectType=article, longId=206332, objectId=f55120633209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f55120633209, replyNumber=0, likeNumber=86, createdTime=2021-01-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f55120633209, moduleTitle=J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f55120633209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255102, encodeId=d4d01255102f0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=友芝友生物PD-L1/TGF-β双特异性抗体新药获得美国FDA临床试验批准, objectType=article, longId=206175, objectId=d62f2061e54a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d62f2061e54a, replyNumber=0, likeNumber=56, createdTime=2021-01-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d62f2061e54a, moduleTitle=友芝友生物PD-L1/TGF-β双特异性抗体新药获得美国FDA临床试验批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d62f2061e54a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2021-11-18

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？

2021-10-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制

2021-10-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究

2021-09-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-09-13

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：α-PD-L1抗体±α-TIM-3抗体治疗MSI-H/dMMR肿瘤的活性和安全性

2021-09-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cell Metab：王红阳院士团队揭示NAD+代谢调节肿瘤免疫逃逸和增强PD-1/PD-L1治疗敏感性

2021-08-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

EBUS-TBNA样品中的PD-L1检测结果是否可以指导ICI治疗？

2021-08-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1测试在使用内核超声引导针吸入（EBUS-TBNA）中获得的大部分标本中是否可行？

2021-08-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况

2021-08-17

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？

2021-08-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Hematol Oncol ：我国不限瘤种PD-L1快要来了，晚期实体瘤患者精准治疗新选择！

2021-07-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JNCI：三种PD-L1免疫组化分析方法对比及与三阴性乳腺癌患者治疗预后的相关性

2021-06-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

陆舜教授：AI多组学深度学习预测肺癌免疫PD-1/PD-L1疗效

2021-03-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

是福是祸？三期临床失败，阿斯利康PD-L1撤回膀胱癌适应症上市资格

2021-02-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：派姆单抗单药治疗PD-L1联合阳性评分≥10的胃/胃食管交界癌的疗效

2021-02-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：新型抗PD-L1抗体LY3300054治疗晚期实体瘤的疗效和安全性

2021-02-05

智慧医人 (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：III期| 派姆单抗联合伊匹单抗治疗PD-L1 TPS≥50%转移性NSCLC（KEYNOTE-598）

2021-02-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌

2021-01-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

友芝友生物PD-L1/TGF-β双特异性抗体新药获得美国FDA临床试验批准

2021-01-25

科室
- - 订阅+
  - 更多科室
工具
服务